Healthcare >> CEO Interviews >> April 6, 2015
David Garrett serves as Vice President, Finance and Corporate Development for Dipexium Pharmaceuticals, Inc. Previously, he served as Managing Partner of Aumoe Partners, LLC, a financial firm he founded. Aumoe Partners served as a financial and business development consultant to Dipexium Pharmaceuticals from January 2012 through the completion of the company’s initial public offering in March 2014. Prior to founding Aumoe Partners, Mr. Garrett served as Principal, Healthcare Equity Sales and Capital Markets at Canaccord Genuity, Inc., from July 2008 to November 2011. From 1999 to 2008, Mr. Garrett served as an equity analyst covering the biotechnology and specialty pharmaceuticals industries at Scudder Kemper Investments, Wachovia Securities, UBS Securities and Fortis Securities. Over the course of his career, Mr. Garrett has assisted over 45 emerging biotechnology and medical technology companies in initial public offerings, secondary public offerings and private placements of public equity that collectively have raised over $2.9 billion. He received a bachelor's degree in economics from the University of Wisconsin-Madison. From 2008 to the present, Mr. Garrett has served on the board of trustees of the Hope Funds for Cancer Research. He also is a member of the organization's executive committee and Chair of its programs committee. Profile
Mr. Garrett: Dipexium Pharmaceuticals was founded in early 2010 around an asset
